Compass Pathways stock surged in pre-market trading, climbing 30.18% to $13.50 as investors reacted to a clustering of company-specific developments tied to its COMP360 psilocybin therapy for treatment-resistant depression.
The company posted first-quarter adjusted earnings per share of -$0.30, beating analyst consensus of -$0.43. That earnings beat arrived alongside a regulatory update: the U.S. Food and Drug Administration has granted a rolling New Drug Application submission and has begun its review. Compass has also been awarded a Commissioner’s National Priority Voucher that could shorten post-filing review timelines.
Compass has submitted at least one of the three required NDA modules and indicated it expects to complete the full submission in the fourth quarter of 2026. Management continues to target a final submission in Q4 2026 and aims for launch readiness by year-end, with Part B 26-week data from the COMP006 Phase 3 trial expected in early Q3 2026.
Analysts have responded favorably to these regulatory and clinical developments. TD Cowen reiterated a Buy rating. RBC Capital raised its price target to $22.00 from $21.00 and kept an Outperform rating, citing a constructive regulatory backdrop and a strong data package. Maxim increased its target to $20 from $12, and Morgan Stanley lifted its target to $17 from $16. Across 11 analysts that cover the company, the average rating is reported as "Strong Buy."
Regulatory mechanics underpin much of the market’s optimism. The Commissioner’s National Priority Voucher is said to enable a one-to-two month FDA review, accelerating timelines after filing. Recent Executive Order guidance also allows the Drug Enforcement Administration’s rescheduling review to proceed in parallel with FDA review. Compass expects COMP360 to be initially reclassified as Schedule 2, with formal rescheduling possibly occurring days after FDA approval.
The broader psychedelics sector has seen a boost from related regulatory signals as well. A White House executive order directing the DEA to accelerate rescheduling reviews for psychedelic treatments that have completed Phase 3 trials has lifted investor interest across the space, supporting sentiment toward companies developing similar therapies.
Notably, Compass’s pre-market advance came while major U.S. indices were trading lower. The S&P 500 and NASDAQ were both down during the same session, indicating that CMPS’s move was driven by company-specific news rather than broader market strength.
Financially, Compass reported cash and cash equivalents of $466 million, which the company says provide a runway into 2028. Management and analysts point to the combination of the earnings beat, an accelerated regulatory pathway, an upcoming investor conference appearance, and a wave of analyst upgrades as a rare confluence of catalysts that has propelled the stock substantially above its prior 52-week high of $11.28.
Investors will be watching the remaining NDA modules and the timing of the full submission, as well as the Part B 26-week data readout expected in early Q3 2026. For now, the convergence of improved near-term financials, regulatory acceleration, and analyst optimism has driven a pronounced pre-market rally in CMPS shares.